Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Truist Securities initiated coverage of Insulet Corporation (NASDAQ:PODD) on Monday with a buy rating and a $365 price target, citing the company’s strong position in the diabetes pump market. According to InvestingPro data, analyst targets range from $260 to $380, with the company maintaining a "GREAT" financial health score.
The research firm highlighted Insulet’s Omnipod 5 platform as the only fully disposable patch pump available, giving the company advantages in both Type 1 diabetes and the potentially accelerating Type 2 diabetes markets.
Truist noted that the global pump opportunity represents a $20 billion market that remains highly underpenetrated, providing significant growth potential for Insulet’s products.
The Omnipod 5’s unique form factor and high-margin recurring revenue model work particularly well in the pharmacy channel, which provides better access benefits for patients, according to Truist’s analysis. InvestingPro subscribers can access 12+ additional exclusive insights about Insulet’s growth potential and financial health in the comprehensive Pro Research Report.
These advantages position Insulet to deliver above-medical-technology-sector revenue growth of more than 18% through 2028 and even faster earnings per share growth exceeding 25%, which Truist characterized as "an elite profile in large-cap MedTech." The company’s market capitalization currently stands at $21.44 billion, with 11 analysts recently revising their earnings estimates upward.
In other recent news, Insulet Corporation has seen a series of analyst updates reflecting confidence in its growth potential. TD Cowen raised its price target for Insulet to $379, maintaining a Buy rating, following a strong first quarter and the appointment of Ashley McEvoy as CEO. Goldman Sachs initiated coverage with a Buy rating and set a price target of $380, citing Insulet’s unique market position in patch pump technology and a promising pipeline that includes potential closed-loop technology. Raymond (NSE:RYMD) James also lifted its price target to $360, highlighting Insulet’s robust growth profile and favorable unit economics. Bernstein increased its target to $375, emphasizing Insulet’s competitive edge with its Omnipod 5 product, particularly in the expanding type 2 diabetes market.
Citi, while maintaining a Buy rating, raised its price target to $380 but removed Insulet from its Top Pick list, shifting focus to Edwards Lifesciences (NYSE:EW) for its upcoming milestones. Analysts across these firms underscore Insulet’s strong market position and innovative technology as key drivers of its anticipated revenue growth. The consistent adjustments in price targets by multiple firms reflect a shared positive outlook on Insulet’s future performance in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.